RxDoctor Payments Data

Randolph Ross

Urology · Hattiesburg, MSNPI 1518076157

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $997 and has fallen 79.8% since, to $202 in 2025. That places this record below the midpoint for urology clinicians in MS, where the typical reported total is $3,535.

$2,270in general payments, 2019–2025

Across 126 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$307
  • Neotract Inc.$266
  • Astellas Pharma US Inc$264
  • Bayer$168
  • Johnson & Johnson$154
  • Coloplast$148
  • plus $962 from 21 others

What the payments were for

  • Food & beverage$2,259100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,270 in reported general payments places this provider in the 40th percentile of 94 urology providers in Mississippi.

See all urology providers in Mississippi

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$33,861
Spiriva RespimatTiotropium Bromide15$7,614
Bevespi AerosphereGlycopyrrolate/Formoterol Fum17$6,804
SymbicortBudesonide/Formoterol Fumarate16$3,335
Albuterol Sulfate HfaAlbuterol Sulfate83$2,441
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,023
Wixela InhubFluticasone Propion/Salmeterol11$1,187
Montelukast Sodium24$111

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$307$33,86151 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 94 urology providers in Mississippi.

Other urology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →